Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Reposting this from -- because it drowns out the noise with facts. Thanks --

From the S-4/A:

"The collaboration will be conducted on an exclusive basis and the parties have agreed not to develop or commercialize any drug product that may be competitive with the Relief Product. "
...
"Pursuant to the Relief Agreement, NeuroRx is responsible for not exceeding the Relief Product trial budget of $8.3 million by more than 30% (approximately $10.7 million) for the original sample size of 144 participants (the ?Initial Budget?)."

"As of May 10, 2021, Relief has reimbursed NeuroRx for approximately $10.6 million of expenses, but has not paid approximately $4 million in invoiced costs associated with conduct of the Relief Product clinical trial, reformulation, and manufacture of ZYESAMI. "

"Each party will continue to own the intellectual property it possessed prior to the collaboration, and any intellectual property that is developed jointly by the parties relating to the Relief Product will be owned jointly by the parties and each party will have the right to use any joint intellectual property in its territory. "

The agreement with $NRXP is quite clear. $RLFTF paid it's share according to the agreement and is entitled to all IP resulting from the collaboration. So any new ZYESAMI formulations are licensed to $RLFTF automatically. ~ WONG, Y@h00 RLFTF finance conversations